Navigation Links
Synthetech Announces New Director of Manufacturing

ALBANY, Ore., Sept. 30 /PRNewswire-FirstCall/ -- Synthetech, Inc. (OTC Bulletin Board: NZYM) announced today the appointment of Dr. Frederic Farkas as Director of Manufacturing effective on October 1, 2008. Since May 2008, Dr. Farkas has provided consulting services to Synthetech. Dr. Farkas has over 13 years' experience with amino acid derivatives, peptides and API manufacturing from previous positions in manufacturing and supply chain management at Bachem Corporation, Novartis AG and Senn Chemicals Company, where he most recently served as Director of Manufacturing. Dr. Farkas earned a Bachelor of Science degree in Chemistry and a Doctor of Philosophy, Organic Chemistry, both from University Basel in Switzerland.

"We are very pleased to have Frederic join Synthetech and contribute his production skills and knowledge," stated Dr. Gregory R. Hahn, President and CEO. "Frederic brings extensive manufacturing management experience from both the pharmaceutical and fine chemical industries."

"I am pleased with the opportunity to improve production performance and continue the turnaround efforts at Synthetech," said Dr. Farkas. "Synthetech has developed an excellent reputation in unnatural amino acids, peptide chemistry and multi-step chiral organic synthesis. I am eager to build on Synthetech's strengths and look forward to meeting the challenge of improving manufacturing efficiencies and costs. I also look forward to working with the Synthetech team to meet both the short- and long-term challenges at Synthetech."

About Synthetech

Synthetech, Inc. is a fine chemicals company specializing in organic synthesis, biocatalysis and chiral technologies. Synthetech develops and manufactures amino acid derivatives, specialty amino acids, peptide fragments, proprietary custom chiral intermediates and specialty resins, primarily for the pharmaceutical industry. Synthetech's products support the development and manufacture of therapeutic peptides and peptidomimetic small molecule drugs at every stage of a customer's clinical development pipeline, and are used as ingredients in drugs for the treatment of AIDS, cancer, cardiovascular and other diseases.



CONTACT: Gary Weber, CFO

PO Box 646

Albany, Oregon 97321

541 967-6575

SOURCE Synthetech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetech Announces Fiscal 2008 Results
2. Synthetech Earns National Recognition for Performance Improvement Program
3. Micromet Announces Definitive Agreement for $40 Million Private Equity Placement
4. Biotel Announces Record Revenues and Earnings for Fiscal 2008
5. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
6. Helix BioPharma Announces $11.4 Million Private Placement
7. ULURU Inc. Announces the Filing of a 510k Submission With the FDA for Altrazeal(TM) Silver
8. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
9. Nomad Bioscience Announces Broad License Agreement
10. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
11. Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA
Post Your Comments:
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the launch of the Supplyframe Design Lab . Located in Pasadena, Calif., ... the future of how hardware projects are designed, built and brought to market. ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... ...
(Date:6/2/2016)... 2, 2016 Perimeter Surveillance & ... Systems, Physical Infrastructure, Support & Other Service  ... offers comprehensive analysis of the global Border ... generate revenues of $17.98 billion in 2016. ... a leader in software and hardware technologies for advanced ...
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
Breaking Biology News(10 mins):